<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36211365</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>11</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>05</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Kynurenine serves as useful biomarker in acute, Long- and Post-COVID-19 diagnostics.</ArticleTitle><Pagination><StartPage>1004545</StartPage><MedlinePgn>1004545</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1004545</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2022.1004545</ELocationID><Abstract><AbstractText Label="INTRODUCTION">In patients with SARS-CoV-2, innate immunity is playing a central role, depicted by hyperinflammation and longer lasting inflammatory response. Reliable inflammatory markers that cover both acute and long-lasting COVID-19 monitoring are still lacking. Thus, we investigated one specific inflammatory marker involved as one key player of the immune system, kynurenine (Kyn), and its use for diagnosis/detection of the Long-/Post-COVID syndrome in comparison to currently used markers in both serum and saliva samples.</AbstractText><AbstractText Label="MATERIAL AND METHODS">The study compromised in total 151 inpatients with a SARS-CoV-2 infection hospitalized between 03/2020 and 09/2021. The group NC (normal controls) included blood bank donors (n=302, 144f/158m, mean age 47.1 &#xb1; 18.3 years (range 18-75)). Two further groups were generated based on Group A (n=85, 27f/58m, mean age 63.1 &#xb1; 18.3 years (range 19-90), acute admission to the hospital) and Group B (n=66, 22f/44m, mean age 66.6 &#xb1; 17.6 years (range 17-90), admitted either for weaning or for rehabilitation period due to Long-COVID symptoms/syndrome). Plasma concentrations of Kyn, C-Reactive Protein (CRP) and interleukin-6 (IL-6) were measured on admission. In Group B we determined Kyn 4 weeks after the negative PCR-test. In a subset of patients (n=11) concentrations of Kyn and CRP were measured in sera and saliva two, three and four months after dismission. We identified 12 patients with Post-COVID symptoms &gt;20 weeks with still significant elevated Kyn-levels.</AbstractText><AbstractText Label="RESULTS">Mean values for NC used as reference were 2.79 &#xb1; 0.61 &#xb5;M, range 1.2-4.1 &#xb5;M. On admission, patients showed significantly higher concentrations of Kyn compared to NC (p-values &lt; 0.001). Kyn significantly correlated with IL-6 peak-values (r=0.411; p-values &lt;0.001) and CRP (r=0.488, p-values&lt;0.001). Kyn values in Group B (Long-/Post-COVID) showed still significant higher values (8.77 &#xb1; 1.72 &#xb5;M, range 5.5-16.6 &#xb5;M), whereas CRP values in Group B were in the normal range.</AbstractText><AbstractText Label="CONCLUSION">Serum and saliva Kyn are reflecting the acute and long-term pathophysiology of the SARS-CoV-2 disease concerning the innate immune response and thus may serve a useful biomarker for diagnosis and monitoring both Long- and Post-COVID syndrome and its therapy.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Bizjak, Stangl, B&#xf6;rner, B&#xf6;sch, Durner, Drunin, Buhl and Abendroth.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bizjak</LastName><ForeName>Daniel Alexander</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Division of Sports and Rehabilitation Medicine, Ulm University Hospital, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stangl</LastName><ForeName>Manfred</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of General, Visceral and Transplant Surgery, Hospital Gro&#xdf;hadern, Ludwig-Maximilians-University, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>B&#xf6;rner</LastName><ForeName>Nikolaus</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Division of General, Visceral and Transplant Surgery, Hospital Gro&#xdf;hadern, Ludwig-Maximilians-University, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>B&#xf6;sch</LastName><ForeName>Florian</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Division of General, Visceral and Transplant Surgery, Hospital Gro&#xdf;hadern, Ludwig-Maximilians-University, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Durner</LastName><ForeName>Joachim</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Neurology Department, Special Medical Clinic Ichenhausen, Ichenhausen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drunin</LastName><ForeName>Gergana</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Neurology Department, Special Medical Clinic Ichenhausen, Ichenhausen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buhl</LastName><ForeName>Jasmine-Leonike</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Division of Sports and Rehabilitation Medicine, Ulm University Hospital, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abendroth</LastName><ForeName>Dietmar</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Surgery, Ulm University Hospital, Ulm, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>343-65-7</RegistryNumber><NameOfSubstance UI="D007737">Kynurenine</NameOfSubstance></Chemical><Chemical><RegistryNumber>8DUH1N11BX</RegistryNumber><NameOfSubstance UI="D014364">Tryptophan</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-41-4</RegistryNumber><NameOfSubstance UI="D002097">C-Reactive Protein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002097" MajorTopicYN="N">C-Reactive Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086742" MajorTopicYN="N">COVID-19 Testing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007737" MajorTopicYN="Y">Kynurenine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014364" MajorTopicYN="N">Tryptophan</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19 monitoring</Keyword><Keyword MajorTopicYN="N">Long-COVID biomarkers</Keyword><Keyword MajorTopicYN="N">inflammation diagnostics</Keyword><Keyword MajorTopicYN="N">innate immunity</Keyword><Keyword MajorTopicYN="N">kynurenine reference values</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>10</Day><Hour>3</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>9</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36211365</ArticleId><ArticleId IdType="pmc">PMC9537769</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2022.1004545</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>
Land WG. Innate alloimmunity. Part 2: Innate immunity and allograft rejection. Lengerich: Pabst Science Publishers;  (2011). Available at: https://www.lehmanns.de/shop/medizin-pharmazie/21802432-9783899677386-innate-alloimmunity-part-2-innate-immunity-and-allograft-rejection.</Citation></Reference><Reference><Citation>Mittal M, Siddiqui MR, Tran K, Reddy SP, Malik AB. Reactive oxygen species in inflammation and tissue injury. Antioxid Redox Signal (2014) 20:1126&#x2013;67. doi:&#xa0;10.1089/ars.2012.5149</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2012.5149</ArticleId><ArticleId IdType="pmc">PMC3929010</ArticleId><ArticleId IdType="pubmed">23991888</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugawara Y, Uehara A, Fujimoto Y, Kusumoto S, Fukase K, Shibata K, et al. . Toll-like receptors, NOD1, and NOD2 in oral epithelial cells. J Dent Res (2006) 85:524&#x2013;9. doi:&#xa0;10.1177/154405910608500609</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/154405910608500609</ArticleId><ArticleId IdType="pubmed">16723649</ArticleId></ArticleIdList></Reference><Reference><Citation>Hippenstiel S, Opitz B, Schmeck B, Suttorp N. Lung epithelium as a sentinel and effector system in pneumonia&#x2013;molecular mechanisms of pathogen recognition and signal transduction. Respir Res (2006) 7:97. doi:&#xa0;10.1186/1465-9921-7-97</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1465-9921-7-97</ArticleId><ArticleId IdType="pmc">PMC1533821</ArticleId><ArticleId IdType="pubmed">16827942</ArticleId></ArticleIdList></Reference><Reference><Citation>Greene CM, Carroll TP, Smith SG, Taggart CC, Devaney J, Griffin S, et al. . TLR-induced inflammation in cystic fibrosis and non-cystic fibrosis airway epithelial cells. J Immunol (2005) 174:1638&#x2013;46. doi:&#xa0;10.4049/jimmunol.174.3.1638</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.174.3.1638</ArticleId><ArticleId IdType="pubmed">15661927</ArticleId></ArticleIdList></Reference><Reference><Citation>Bektas A, Schurman SH, Franceschi C, Ferrucci L. A public health perspective of aging: do hyper-inflammatory syndromes such as COVID-19, SARS, ARDS, cytokine storm syndrome, and post-ICU syndrome accelerate short- and long-term inflammaging? Immun Ageing (2020) 17:23. doi:&#xa0;10.1186/s12979-020-00196-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12979-020-00196-8</ArticleId><ArticleId IdType="pmc">PMC7443812</ArticleId><ArticleId IdType="pubmed">32849908</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu J, Gong E, Zhang B, Zheng J, Gao Z, Zhong Y, et al. . Multiple organ infection and the pathogenesis of SARS. J Exp Med (2005) 202:415&#x2013;24. doi:&#xa0;10.1084/jem.20050828</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20050828</ArticleId><ArticleId IdType="pmc">PMC2213088</ArticleId><ArticleId IdType="pubmed">16043521</ArticleId></ArticleIdList></Reference><Reference><Citation>Savitz J. The kynurenine pathway: A finger in every pie. Mol Psychiatry (2020) 25:131&#x2013;47. doi:&#xa0;10.1038/s41380-019-0414-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-019-0414-4</ArticleId><ArticleId IdType="pmc">PMC6790159</ArticleId><ArticleId IdType="pubmed">30980044</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervenka I, Agudelo LZ, Ruas JL. Kynurenines: Tryptophan&#x2019;s metabolites in exercise, inflammation, and mental health. Science (2017) 357:34. doi:&#xa0;10.1126/science.aaf9794</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaf9794</ArticleId><ArticleId IdType="pubmed">28751584</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirthgen E, Hoeflich A, Rebl A, G&#xfc;nther J. Kynurenic acid: The janus-faced role of an immunomodulatory tryptophan metabolite and its link to pathological conditions. Front Immunol (2017) 8:1957. doi:&#xa0;10.3389/fimmu.2017.01957</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.01957</ArticleId><ArticleId IdType="pmc">PMC5770815</ArticleId><ArticleId IdType="pubmed">29379504</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S-M, Park HY, Suh Y-S, Yoon EH, Kim J, Jang WH, et al. . Inhibition of acute lethal pulmonary inflammation by the IDO-AhR pathway. Proc Natl Acad Sci U.S.A. (2017) 114:E5881&#x2013;90. doi:&#xa0;10.1073/pnas.1615280114</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1615280114</ArticleId><ArticleId IdType="pmc">PMC5530642</ArticleId><ArticleId IdType="pubmed">28673995</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Guillemin GJ. Kynurenine pathway metabolites in humans: Disease and healthy states. Int J Tryptophan Res (2009) 2:1&#x2013;19. doi:&#xa0;10.4137/ijtr.s2097</Citation><ArticleIdList><ArticleId IdType="doi">10.4137/ijtr.s2097</ArticleId><ArticleId IdType="pmc">PMC3195227</ArticleId><ArticleId IdType="pubmed">22084578</ArticleId></ArticleIdList></Reference><Reference><Citation>Bou&#xe7;as AP, Rheinheimer J, Lagopoulos J. Why severe COVID-19 patients are at greater risk of developing depression: A molecular perspective. Neuroscientist (2022) 28:11&#x2013;9. doi:&#xa0;10.1177/1073858420967892</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1073858420967892</ArticleId><ArticleId IdType="pubmed">33135582</ArticleId></ArticleIdList></Reference><Reference><Citation>V&#xe9;n&#xe9;reau E, Ceriotti C, Bianchi ME. DAMPs from cell death to new life. Front Immunol (2015) 6:422. doi:&#xa0;10.3389/fimmu.2015.00422</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2015.00422</ArticleId><ArticleId IdType="pmc">PMC4539554</ArticleId><ArticleId IdType="pubmed">26347745</ArticleId></ArticleIdList></Reference><Reference><Citation>Harwood R, Allin B, Jones CE, Whittaker E, Ramnarayan P, Ramanan AV, et al. . A national consensus management pathway for paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS): results of a national Delphi process. Lancet Child Adolesc Health (2021) 5:133&#x2013;41. doi:&#xa0;10.1016/S2352-4642(20)30304-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-4642(20)30304-7</ArticleId><ArticleId IdType="pmc">PMC7500943</ArticleId><ArticleId IdType="pubmed">32956615</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. . Clinical course and risk factors for mortality of adult inpatients with COVID-19 in wuhan, China: A retrospective cohort study. Lancet (2020) 395:1054&#x2013;62. doi:&#xa0;10.1016/S0140-6736(20)30566-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30566-3</ArticleId><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z-L, Hou Y-L, Li D-T, Li F-Z. Laboratory findings of COVID-19: A systematic review and meta-analysis. Scand J Clin Lab Invest (2020) 80:441&#x2013;7. doi:&#xa0;10.1080/00365513.2020.1768587</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00365513.2020.1768587</ArticleId><ArticleId IdType="pmc">PMC7256350</ArticleId><ArticleId IdType="pubmed">32449374</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang W, Liang H, Ou L, Chen B, Chen A, Li C, et al. . Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19. JAMA Intern Med (2020) 180:1081&#x2013;9. doi:&#xa0;10.1001/jamainternmed.2020.2033</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2020.2033</ArticleId><ArticleId IdType="pmc">PMC7218676</ArticleId><ArticleId IdType="pubmed">32396163</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan L, Zhang H-T, Goncalves J, Xiao Y, Wang M, Guo Y, et al. . An interpretable mortality prediction model for COVID-19 patients. Nat Mach Intell (2020) 2:283&#x2013;8. doi:&#xa0;10.1038/s42256-020-0180-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42256-020-0180-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Aziz M, Fatima R, Assaly R. Elevated interleukin-6 and severe COVID-19: A meta-analysis. J Med Virol (2020) 92:2283&#x2013;5. doi:&#xa0;10.1002/jmv.25948</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25948</ArticleId><ArticleId IdType="pmc">PMC7267383</ArticleId><ArticleId IdType="pubmed">32343429</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu J, Pang J, Ji P, Zhong Z, Li H, Li B, et al. . Elevated interleukin-6 is associated with severity of COVID-19: A meta-analysis. J Med Virol (2021) 93:35&#x2013;7. doi:&#xa0;10.1002/jmv.26085</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26085</ArticleId><ArticleId IdType="pmc">PMC7283812</ArticleId><ArticleId IdType="pubmed">32470146</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. . Attributes and predictors of long COVID. Nat Med (2021) 27:626&#x2013;31. doi:&#xa0;10.1038/s41591-021-01292-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01292-y</ArticleId><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendelson M, Nel J, Blumberg L, Madhi SA, Dryden M, Stevens W, et al. . Long-COVID: An evolving problem with an extensive impact. S Afr Med J (2020) 111:10&#x2013;2. doi:&#xa0;10.7196/SAMJ.2020.v111i11.15433</Citation><ArticleIdList><ArticleId IdType="doi">10.7196/SAMJ.2020.v111i11.15433</ArticleId><ArticleId IdType="pubmed">33403997</ArticleId></ArticleIdList></Reference><Reference><Citation>Maglietta G, Diodati F, Puntoni M, Lazzarelli S, Marcomini B, Patrizi L, et al. . Prognostic factors for post-COVID-19 syndrome: A systematic review and meta-analysis. J Clin Med (2022) 11:1541&#x2013;56. doi:&#xa0;10.3390/jcm11061541</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11061541</ArticleId><ArticleId IdType="pmc">PMC8948827</ArticleId><ArticleId IdType="pubmed">35329867</ArticleId></ArticleIdList></Reference><Reference><Citation>Herridge MS, Tansey CM, Matt&#xe9; A, Tomlinson G, Diaz-Granados N, Cooper A, et al. . Functional disability 5 years after acute respiratory distress syndrome. N Engl J Med (2011) 364:1293&#x2013;304. doi:&#xa0;10.1056/NEJMoa1011802</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1011802</ArticleId><ArticleId IdType="pubmed">21470008</ArticleId></ArticleIdList></Reference><Reference><Citation>Boomer JS, Green JM, Hotchkiss RS. The changing immune system in sepsis: is individualized immuno-modulatory therapy the answer? Virulence (2014) 5:45&#x2013;56. doi:&#xa0;10.4161/viru.26516</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/viru.26516</ArticleId><ArticleId IdType="pmc">PMC3916383</ArticleId><ArticleId IdType="pubmed">24067565</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies MG, Hagen PO. Systemic inflammatory response syndrome. Br J Surg (1997) 84:920&#x2013;35. doi:&#xa0;10.1002/bjs.1800840707</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bjs.1800840707</ArticleId><ArticleId IdType="pubmed">9240130</ArticleId></ArticleIdList></Reference><Reference><Citation>Hotchkiss RS, Monneret G, Payen D. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis (2013) 13:260&#x2013;8. doi:&#xa0;10.1016/S1473-3099(13)70001-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(13)70001-X</ArticleId><ArticleId IdType="pmc">PMC3798159</ArticleId><ArticleId IdType="pubmed">23427891</ArticleId></ArticleIdList></Reference><Reference><Citation>Almulla AF, Supasitthumrong T, Tunvirachaisakul C, Algon AA, Al-Hakeim HK, Maes M. The tryptophan catabolite or kynurenine pathway in COVID-19 and critical COVID-19: A systematic review and meta-analysis. BMC Infect Dis (2022) 22:615. doi:&#xa0;10.1186/s12879-022-07582-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-022-07582-1</ArticleId><ArticleId IdType="pmc">PMC9284970</ArticleId><ArticleId IdType="pubmed">35840908</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaden J, Abendroth D, V&#xf6;lp A, Marzinzig M. Dynamics and diagnostic relevance of kynurenine serum level after kidney transplantation. Ann Transplant (2015) 20:327&#x2013;37. doi:&#xa0;10.12659/AOT.893721</Citation><ArticleIdList><ArticleId IdType="doi">10.12659/AOT.893721</ArticleId><ArticleId IdType="pubmed">26062734</ArticleId></ArticleIdList></Reference><Reference><Citation>
Abendroth D, Stangl MJ, Marzinzig M. WO2014177680 - in vitro method for the early detection of a potential inflammation, in particular associated with rejection of a transplant, a neurodegenerative disorder or a depression (WO/2014/177680) (2014). Available at: https://www.mysciencework.com/patent/download/vitro-method-early-detection-potential-inflammation-associated-rejection-transplant-EP2992332B1/EP2992332B1 (Accessed cited 2022 Aug 18).</Citation></Reference><Reference><Citation>Garc&#xed;a LF. Immune response, inflammation, and the clinical spectrum of COVID-19. Front Immunol (2020) 11:1441. doi:&#xa0;10.3389/fimmu.2020.01441</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.01441</ArticleId><ArticleId IdType="pmc">PMC7308593</ArticleId><ArticleId IdType="pubmed">32612615</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawler NG, Gray N, Kimhofer T, Boughton B, Gay M, Yang R, et al. . Systemic perturbations in amine and kynurenine metabolism associated with acute SARS-CoV-2 infection and inflammatory cytokine responses. J Proteome Res (2021) 20:2796&#x2013;811. doi:&#xa0;10.1021/acs.jproteome.1c00052</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jproteome.1c00052</ArticleId><ArticleId IdType="pubmed">33724837</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas T, Stefanoni D, Reisz JA, Nemkov T, Bertolone L, Francis RO, et al. . COVID-19 infection alters kynurenine and fatty acid metabolism, correlating with IL-6 levels and renal status. JCI Insight (2020) 5. doi:&#xa0;10.1172/jci.insight.140327</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.140327</ArticleId><ArticleId IdType="pmc">PMC7453907</ArticleId><ArticleId IdType="pubmed">32559180</ArticleId></ArticleIdList></Reference><Reference><Citation>Bizjak DA, Treff G, Z&#xfc;gel M, Schumann U, Winkert K, Schneider M, et al. . Differences in immune response during competition and preparation phase in elite rowers. Front Physiol (2021) 12:803863. doi:&#xa0;10.3389/fphys.2021.803863</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2021.803863</ArticleId><ArticleId IdType="pmc">PMC8718927</ArticleId><ArticleId IdType="pubmed">34975545</ArticleId></ArticleIdList></Reference><Reference><Citation>Chertow D, Stein S, Ramelli S, Grazioli A, Chung J-Y, Singh M, et al. . SARS-CoV-2 infection and persistence throughout the human body and brain. (2021). doi: 10.21203/rs.3.rs-1139035/v1</Citation><ArticleIdList><ArticleId IdType="doi">10.21203/rs.3.rs-1139035/v1</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C, Darley DR, Wilson DB, Howe A, Munier CM, Patel SK, et al. . Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol (2022) 23:210&#x2013;6. doi:&#xa0;10.1038/s41590-021-01113-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01113-x</ArticleId><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>Perkins E, Davison G. Epstein-Barr Virus (EBV) DNA as a potential marker of in vivo immunity in professional footballers. Res Q Exerc Sport (2021), 1&#x2013;8. doi:&#xa0;10.1080/02701367.2021.1932707</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/02701367.2021.1932707</ArticleId><ArticleId IdType="pubmed">34806947</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannos P, Prokopidis K. Gut dysbiosis and long COVID-19: Feeling gutted. J Med Virol (2022) 94:2917&#x2013;8. doi:&#xa0;10.1002/jmv.27684</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27684</ArticleId><ArticleId IdType="pmc">PMC9088471</ArticleId><ArticleId IdType="pubmed">35233795</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson G, Maes M. Gut dysbiosis dysregulates central and systemic homeostasis via suboptimal mitochondrial function: Assessment, treatment and classification implications. Curr Top Med Chem (2020) 20:524&#x2013;39. doi:&#xa0;10.2174/1568026620666200131094445</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1568026620666200131094445</ArticleId><ArticleId IdType="pubmed">32003689</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson G. Tumour microenvironment: Roles of the aryl hydrocarbon receptor, O-GlcNAcylation, acetyl-CoA and melatonergic pathway in regulating dynamic metabolic interactions across cell types-tumour microenvironment and metabolism. Int J Mol Sci (2020) 22:141&#x2013;71. doi:&#xa0;10.3390/ijms22010141</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22010141</ArticleId><ArticleId IdType="pmc">PMC7795031</ArticleId><ArticleId IdType="pubmed">33375613</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-Casta&#xf1;eda A, Lu P, Geraghty AC, Song E, Lee M-H, Wood J, et al. . Mild respiratory SARS-CoV-2 infection can cause multi-lineage cellular dysregulation and myelin loss in the brain. (2022). doi:&#xa0;10.1101/2022.01.07.475453</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.01.07.475453</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka M, V&#xe9;csei L. Monitoring the kynurenine system: Concentrations, ratios or what else? Adv Clin Exp Med (2021) 30:775&#x2013;8. doi:&#xa0;10.17219/acem/139572</Citation><ArticleIdList><ArticleId IdType="doi">10.17219/acem/139572</ArticleId><ArticleId IdType="pubmed">34418336</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson G, Carbone A, Mazzoccoli G. Tryptophan metabolites and aryl hydrocarbon receptor in severe acute respiratory syndrome, coronavirus-2 (SARS-CoV-2) pathophysiology. Int J Mol Sci (2021) 22:1597&#x2013;1613. doi:&#xa0;10.3390/ijms22041597</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22041597</ArticleId><ArticleId IdType="pmc">PMC7915649</ArticleId><ArticleId IdType="pubmed">33562472</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>